Wockhardt experiences a revenue hit after MHRA concerns on Nani Daman facility

The Mumbai based pharma major Wockhardt announced that there would be a revenue hit of nearly one million pounds after the import restrictions imposed on its Nani Daman facility in Gujarat.

Last month, the UK health regulator, Medicine and Healthcare Products Regulatory Agency (MHRA) imposed import restrictions on medicines manufactured at Kadaiya facility of Wockhardt in Nani Daman in Gujarat. These restrictions were a result of violations of good manufacturing practice (GMP) norms. This facility of the company was another one to be facing the heat of health regulators due to GMP compliance issues after Chikalthana and Waluj facility in Maharashtra.

While the revenue hit continues, the company announced that MHRA has eased on the restrictions to a certain extent. The company is now allowed to supply most of the products that are manufactured at the company’s said facility to the UK market. The company announced that a communication from the MHRA has been received, wherein the company is permitted the manufacturing and supplying of most of the products that have been assessed as critical to public health to the UK.